Read the quarter in context.
A source-linked quarter view: reported numbers, management language, guidance, and the risks that should carry forward.
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Revenue
₹1,028 Cr
verified against source
Revenue YoY
10%
reported change
EBITDA
₹291 Cr
latest reported figure
Source
screener in
record provenance
Actual signal trajectory
Where this quarter sits.
Quarter read
What the record says.
Ajanta Pharma delivered a solid Q2 FY24 with consolidated revenue of INR 1,028 crore (+10% YoY) and EBITDA of INR 291 crore (+48% YoY), driven by strong US generics growth (+28% YoY) and margin expansion from lower logistics costs and favorable forex. India branded business grew 13% YoY, outpacing IPM by 400 bps. Management guided for low-teens growth in Asia and Africa branded businesses for FY24, and US revenues to sustain at similar levels for the next two quarters. EBITDA margin guidance was upgraded to ~26% for FY24. Key risk: Asia branded business saw an 8% YoY decline due to shipment push-outs, though recovery is expected in H2.
Colored figures show movement against the previous available record.
Guidance to track
- Management expects EBITDA margin of around 26% for FY24, up from earlier guidance of 25%, due to improved gross margins and lower logistics costs.
- Despite an 8% decline in Q2, management expects Asia branded business to post low-teens growth for the full year, driven by recovery in H2.
- Africa branded business is expected to bounce back and deliver low-teens growth for FY24, after a flattish H1.
- Management expects US generics revenue to remain at Q2 levels for the next two quarters, factoring in new launches and market share changes.
Risks flagged
- Asia branded sales declined 8% YoY in Q2 due to supplies pushed to next quarter; recovery depends on execution.
- Africa branded business saw a slowdown in the market over the last 4-5 months; growth recovery is uncertain.
- Chantix launch is delayed to Q4 FY24 or Q1 FY25; any further delay could impact US revenue expectations.
- Management confirmed high single-digit price erosion in US base portfolio, which could pressure margins if volumes don't compensate.
Key quotes
- The customers are valuing the consistent supplier of high quality with high compliance rate over the prices of reducing by a few cents or few percentages.
- We continue to outpace IPM by 400 basis points, with Ajanta growing at 14%, surpassing the IPM growth of 10% as per IQVIA MAT, September 2023.
- We believe that the worst is behind us. Market has stabilized to a great extent.
Research modules